Background: Mutations in the peripherin/retinal degeneration slow (RDS) gene have been identified in patients with retinitis pigmentosa and pattern macular dystrophy. The authors initially examined a large family affected with both peripheral and macular degeneration, inherited as an autosomal dominant trait. Screening for peripherin/RDS mutations identified a previously unreported nucleotide alteration in all of the affected individuals. Two additional families later were found to have this same mutation.
The retinal degeneration slow (RDS) gene was first identified in the rds mouse, which manifests a semidominant retinal degeneration. The RDS gene product is peripherin, I which is an integral membrane protein present in the rim region of the outer segments of both rod and cone photoreceptors.
The recent identification of mutations in the photoreceptor-specific gene rhodopsin 2 -4 stimulated investigators to screen the peripherin/RDS gene for mutations in families with retinitis pigmentosa. Many disease-causing mutations were found.
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The expansion of this candidate gene screening to patients with other retinal and pigment epithelial dystrophies showed a spectrum of phenotypes to be associated with different peripherin/RDS mutations, including butterfly-shaped pigment epithelial dystrophy8 and pametinal degener- 9 Although the function ofperipherin/RDS is unknown, it may stabilize outer segment discs through interactions with other membrane-associated proteins.lo,11 Because these interactions may involve other cone-or rod-specific proteins, there is the potential for peripherin/RDS mutations to have differential effects on the rod and cone photoreceptor cell populations.
In almost all previous reports of peripherin/RDS mutations, affected individuals within a family have shared common phenotypes with varying degrees of severity. Recently, a family was reported in which a single peripherin/RDS mutation was associated with retinitis pigmentosa, pattern dystrophy, or fundus flavimaculatus in different affected family members. 12 In this report, a new peripherin/RDS mutation is found to be associated with a broad spectrum of clinical phenotypes within the same family. Figure 2 . Comparison of the nucleotide sequencing of the normal and affected exon-2 polymerase chain reaction (PCR) products. On the left is the derived amino acid sequence and nucleotide sequence of the peripherin/ retinal degeneration slow PCR product from a heterozygous, affected individual. On the right is the corresponding sequencing gel, nucleotide sequence, and derived amino acid sequence for thenormalperipherin/ retinal degeneration slow peR product.
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Figure 3. Single-strand conformation analysis of the polymerase chain reaction products for peripherin/ retinal degeneration slow exon 2. Notice the additional bands (arrow) with altered mobilities in the lanes corresponding to the affected members of the family. The pedigree numbers correspond to those in Figures 1, 2 , and 3.
Patients and Methods
The proband of the largest family (family 1) was a 41-year-old white woman who had visual blurring for I year and who initially had received a diagnosis of fundus tlavimaculatus. Upon further questioning, it was apparent that a number of other family members had had central visual loss, and a family study was undertaken. The majority of the family members initially were screened at a large family reunion_ The complete pedigree of this family is shown in Figure 1 . Medical histories, informed consents, and blood samples either were taken at the time of the screening or in person's homes. Whenever possible, affected individuals had more extensive evaluations, including color testing, visual fields, fundus photography, and angiography_ Electroretinography and electrooculography were performed on a subset of these individuals. Blood samples also were obtained from members of two other families affected with an autosomal dominant macular dystrophy. Family 2 originally was described by Gass et al, 13 defining the entity known as peculiar foveomacular dystrophy. Family 3 consists of a woman, who was originally believed to have Stargardt disease, and her son.
DNA Studies
Genomic DNA was purified from peripheral blood lymphocytes by standard methods using the Applied Biosysterns 340 DNA extractor (Applied Biosystems, Inc, Foster City, CA). The primer sequences used for GC-clamped denaturing gel electrophoresis (DGGE) analysis of the peripherin/RDS gene previously were reported by Nichols et al, 8 whereas those used for SSCP analysis previously were reported Wells et al. Ten J-Ll formamide loading buffer was added to the PCR product. After denaturation at 80°C for 3 minutes, 3 J-Ll of each sample was loaded on a nondenaturing 6% polyacrylamide gel. Electrophoresis was carried out for 16 hours at room temperature. The gel was transferred on to 3-mm filter paper (Whatman, Inc, Clifton, NJ) and dried using a heated gel dryer in vacuo. Autoradiographs were made by exposing Kodak X-OMAT AR film to the dried gel for 24 to 48 hours. Denaturing gradient gel electrophoresis and DNA sequencing were performed as described by Nichols et al. 8 
Results

Denaturing Gel Electrophoresis and SSCP Analyses
GC-clamped DGGE 14 • 15 screening of the complete peripherin/RDS coding sequence in two affected individuals from each of the three families identified the existence of a mutation in exon 2 in all of them. Direct DNA sequencing of the exon 2 PCR products of one individual in each family showed the sequence change to be a C to G transversion mutation in the second nucleotide of codon 2 I 0, resulting in the substitution of arginine for proline (Pro-210-Arg) at this position (Fig 2) . SSCP analysis then was used to screen all available family members of family I, and the mutation was identified in 17 individuals, including all 14 clinically affected patients (Fig 3) . This mutation was not detected in 100 control individuals (200 chromosomes-data not shown).
Clinical Phenotypes
Fifty-one members of family I were examined. The 12 clinically affected family members ranged in age from 16 to 75 years. Table I lists some of the clinical features and visual function test results in these affected individuals. Figure 4 illustrates the macular findings in the affected individuals. Retinal findings included diffuse, fine, hard drusen in the macula; a butterfly pattern; extensive retinal atrophy; diffuse pigment epithelial disturbances; and severe atrophic macular degeneration. Fluorescein angiography detected subtle abnormalities in the fovea of the youngest molecularly affected individual (V-lO) (Fig 4) and in the individual with extensive fine drusen. In other individuals, the fluorescein angiograms showed widespread pigment epithelial alterations or parafoveal disturbances, without staining of the vitelliform lesions. Similar to the family reported by Nichols et al, 8 there were no cases of choroidal neovascularization. Five individuals with normal results of fundus examinations, including one 39-year-old individual, were found to harbor the peripherin/RDS mutation.
Visual function varied considerably among the members offamily I with the mutation. Visual acuities ranged from 20/20 to less than 20/200. Central visual loss seemed to correlate with the degree of central retinal atrophy. As shown in Figure 5 , peri metric findings also varied widely. Severe peripheral field loss was documented in several members of the pedigree, whereas other affected individuals showed general threshold elevation and/or central/paracentral scotomas. Eleven patients in family I underwent electroretinography. Only one had normal responses. The other ten individuals showed rod and cone system abnormalities, some having more cone than rod dysfunction. The electrooculograms were normal in 4 of II persons tested. The Arden ratios were between 1.5 and 2.0 for five persons and below 1.5 for two.
The fundus features of many of the affected members of family I are identical to those of family 2 who were initially described by Gass as having peculiar foveomacular dystrophy.13 Affected individuals in family 2 ranged in age from 30 to 70 years and had well-preserved visual acuities (range, 20/25-20/50). The onset of symptoms ranged from 24 to 44 years of age, and the visual disturbances were slowly progressive.
The proband of family 3 initially was seen at 44 years of age with a I-year history of metamorphopsia. Fig 4) , he had small yellowish subfoveal lesions in each eye. Five years later, there was increased prominence of the subfoveallesions and some early peripheral flecks. His visual acuity remained 20/ 25 in both eyes.
Discussion
Clinical Heterogeneity of a Single Peripherin/ Retinal Degeneration Slow Mutation Within a single family, most peripherin/RDS mutations have a fairly homogeneous phenotype, with only age-dependent variations of severity. 7.8 However, Weleber et al 12 recently reported a family in which a deletion of codon 153 was associated with three distinct phenotypes. The Pro-21O-Arg mutation in this report has a similar intrafamilial variability. A number of individuals in family I initially were seen by ophthalmologists who were unaware of the nature of the retinal disease in other family members. The diagnoses made in this single-patient setting included age-related macular degeneration, retinitis pigmentosa, Stargardt disease, adult vitelliform degeneration, dominant drusen, and pattern dystrophy. The youngest symptomatic individual in family I was 16 years of age at the time of evaluation (patient V-I 0, Fig 4) . In contrast, individual IV-24, carried the Pro-21O-Arg mutation but had no visual symptoms or electrophysiologic or fundus abnormalities at 39 years of age. Several affected individuals in family 1 with fundus abnormalities had normal visual acuities and few or no visual symptoms even in the sixth decade of life (Table I ). Only two of the affected individuals in family I, III-08 and IV-20, were sufficiently impaired that they could not legally drive.
The two individuals from family 3 illustrate that the Pro-21O-Arg mutation can be associated with fairly severe visual loss as well as early onset of retinal pathology. The best visual acuity of the proband's best eye was 20/100 at 50 years of age, and her II-year-old son had reduced visual acuity of 20/25 at II years of age.
The complete lack of penetrance of the mutant gene in one 39-year-old patient and its mild expression in several others should not raise doubts about the involvement of the peripherin/RDS gene in the retinal disease of these three families. Every clinically affected family member whose DNA was available for testing was found to harbor the mutation (18/18 patients). The odds of this association occurring by chance are less than I in 10,000. The other factors that argue strongly for the pathogenicity of the Pro-21O-Arg mutation are (1) its discovery in three unrelated but phenotypically similar families; (2) its absence in control individuals; and (3) Figure  I and Table 1 . Relation of Photoreceptor Genes to Age~related Macular Degeneration
Our findings provide additional evidence that a photoreceptor-specific gene can cause a primarily macular disease. Other proteins involved in the phototransduction pathway and photoreceptor structure may interact with peripherin, and polymorphisms within such proteins may explain the range of disease phenotypes seen within a single family. The histopathologic studies conducted by contribute to the development of progressive macular disease. Macular degeneration also has been observed in individuals with deletions in the red cone pigment gene on the X-chromosome. '8 An autosomal dominant, Stargardt's-like macular disease recently has been linked to chromosome 13'9 and chromosome 6. 20 .
The role of photoreceptor-specific genes in the development of age-related macular degeneration is unknown. The demonstration of macular degeneration associated with multiple peripherinjRDS mutations expands the potential role of the photoreceptors in the pathogenesis of this disorder. Age-related macular degeneration is a clinically heterogeneous set of disorders that frequently demonstrates autosomal dominant patterns of inheritance?' Although many investigators have emphasized pigment epithelial dysfunction and basement membrane abnormalities as potential causes of age-related macular degeneration,22,23 it is clear that genes expressed anywhere within the entire retina~pigment epithelium-choriocap-254 illaris complex are potential candidates for involvement in the pathogenesis of age--related macular degeneration.
